Welcome to our dedicated page for AgomAb Therapeutics NV SEC filings (Ticker: AGMB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on AgomAb Therapeutics NV's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into AgomAb Therapeutics NV's regulatory disclosures and financial reporting.
Agomab Therapeutics NV director David R. Epstein filed an initial ownership report showing stock options over common shares. He holds options covering 770,671 shares at an exercise price of $2.8100 expiring on July 8, 2034, 217,295 shares at $5.2600 expiring on November 4, 2034, and 38,843 shares at $14.2600 expiring on January 15, 2036. Footnotes describe multi-year vesting schedules and note that common shares may be represented by American Depositary Shares on a one-for-one basis.
Agomab Therapeutics NV director and Chief Executive Officer Tim Jasper Knotnerus filed an initial ownership report showing his equity position in the company. The filing lists multiple stock options to buy common shares with exercise prices of $1.1300, $0.0005 and $14.2600, expiring between 2029 and 2036. Some options are fully vested and exercisable, while others vest over time based on continued service. He also reports holding 10,823 common shares directly and 34,394 common shares indirectly through TJK Life Sciences B.V., over which he has voting and dispositive power but disclaims beneficial ownership except for any pecuniary interest.
Agomab Therapeutics NV director Colin Michael Bond filed an initial Form 3 showing holdings of stock options over common shares. He holds options over 96,321 shares with a $3.1800 exercise price and 27,165 shares at $5.2600, both expiring on November 4, 2034, plus 27,921 shares at $14.2600 expiring on January 15, 2036. Footnotes explain that portions of these options vest over time, subject to continued service, that common shares may be represented by American Depositary Shares on a one‑for‑one basis, and that exercise prices are reported in U.S. dollars based on a stated euro conversion rate.
Agomab Therapeutics NV director Hammer Ohad has reported an initial equity position consisting of stock options. These options allow him to buy up to 27,921 common shares at an exercise price of $14.2600 per share until January 15, 2036.
According to the vesting terms, 33% of the shares underlying this option will vest on February 9, 2027, with the remaining shares vesting in 24 equal monthly installments thereafter, subject to his continued service. The common shares may be represented by American Depositary Shares, each currently representing one common share, and the exercise price reflects conversion from euros to U.S. dollars at a stated exchange rate.
Agomab Therapeutics NV’s Chief Financial Officer Pierre Thadee Victor Kemula reported existing stock option holdings in a Form 3. The filing shows three option awards over 289,005, 102,057 and 191,958 common shares at exercise prices of $2.7600, $3.1800 and $14.2600, expiring between July 8, 2034 and January 15, 2036. Footnotes describe time-based vesting, including one grant where 50% of the underlying shares vested on February 9, 2026 with the balance vesting in 24 monthly installments, and another where 25% vests on February 9, 2027 followed by 36 monthly installments. The options relate to common shares, which may be represented by American Depositary Shares on a one-for-one basis.
Agomab Therapeutics director Angelika Martha Jahreis reported her existing stock option holdings in a Form 3. She holds several options over common shares, including 94,438 shares at an exercise price of $3.10 per share expiring on October 10, 2033. Other options cover 1,884, 27,165 and 31,505 underlying shares with exercise prices from $2.81 to $14.26 and expirations between July 8, 2034 and January 15, 2036. Footnotes state some options are fully vested, while others vest in scheduled monthly installments from February 9, 2026 and February 9, 2027, contingent on continued service.
Agomab Therapeutics NV Chief Business Officer Paul Henryk van der Horst has reported his derivative equity holdings in a Form 3. The filing lists several stock options to buy Agomab common shares at exercise prices of $0.0005 and $14.2600 per share.
The options cover different blocks of underlying common shares, with expiration dates ranging from 2031-03-05 through 2036-01-15. Footnotes state that some shares underlying these options are fully vested and exercisable, while others vest over time in monthly installments, subject to his continued service.
Agomab Therapeutics NV director Verduyn-van Weegen Felice Isabel reported an initial stock option holding for 32,700 common shares. The option has an exercise price of $14.2600 per share and expires on January 15, 2036.
According to the filing, 33% of the underlying shares vest on February 9, 2027, with the remainder vesting in 24 equal monthly installments, subject to continued service. The common shares may be represented by American Depositary Shares, each currently representing one common share.
Agomab Therapeutics NV filed an initial ownership report for Chief Development Officer Andrea Saez Borderias, detailing multiple stock option awards over common shares. The options are held directly, with exercise prices of $0.0005 and $14.2600 per share and expirations ranging from 2031 to 2036. Footnotes state that some options are already fully vested and exercisable, while others vest over time in scheduled monthly installments, conditioned on continued service. The common shares may also be represented by American Depositary Shares on a one-for-one basis.
Agomab Therapeutics NV General Counsel Ellen Lefever filed an initial statement of beneficial ownership, detailing several stock option awards over common shares. These options give rights to buy AGMB shares at exercise prices including $2.7600, $3.1800 and $14.2600, with expirations from 2031 through 2036.
One grant covers 91,256 underlying common shares at $2.7600 per share expiring on March 5, 2031, and another covers 127,972 shares at $14.2600 expiring on January 15, 2036, all held directly. Footnotes note that some options are fully vested while others vest over time, that common shares may be represented by ADSs on a 1:1 basis, and that exercise prices are reported in U.S. dollars using a stated EUR/USD exchange rate.